Sulphasalazine in rheumatoid arthritis.

Sulphasalazine treatment in rheumatoid arthritis.

Sulphasalazine induced hepatitis in juvenile rheumatoid arthritis.

Two 19 year old patients with juvenile chronic arthritis developed liver toxicity during treatment with sulphasalazine. A significant increase in the levels of liver enzymes in serum samples was noticed in relation to the initiation of treatment in one patient and to the increase in dose in the second. The enzymes returned to normal levels 14 days after the drug had been stopped. A rechallenge ...

Leucopenia during sulphasalazine treatment for rheumatoid arthritis.

Leucopenia appears to be a more frequent complication of sulphasalazine treatment in rheumatoid arthritis than in inflammatory bowel disease and poses a management problem. In this study leucopenia was found in 20 patients, 14 of whom were participating in prospective studies (252 patients), giving an incidence of 5.6%. Treatment had to be discontinued in half of these patients. Most (14) episo...

Sulphasalazine induced selective IgA deficiency in rheumatoid arthritis.

and the mean observed peak plasma metoprolol concentration by about 33%. Furthermore, the elimination half life of metoprolol was prolonged from 3-9 hours during monotreatment to 6-0 hours when ranitidine was given in combination (p<0005). There was no evidence that any of the volunteers were poor metabolisers of metoprolol. Beta-blockade was assessed on the sixth treatment day by examining the...

Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate.

Uncontrolled studies have suggested that sulphasalazine may be an effective second line agent in rheumatoid arthritis. Sulphasalazine was therefore compared with placebo and intramuscular sodium aurothiomalate in 90 patients with active rheumatoid arthritis. After six months' treatment both sulphasalazine and sodium aurothiomalate had produced significant clinical and laboratory benefit, wherea...